These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23676589)

  • 41. Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis.
    Yarur AJ; Jain A; Hauenstein SI; Quintero MA; Barkin JS; Deshpande AR; Sussman DA; Singh S; Abreu MT
    Inflamm Bowel Dis; 2016 Feb; 22(2):409-15. PubMed ID: 26752470
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
    Narula N; Kainz S; Petritsch W; Haas T; Feichtenschlager T; Novacek G; Eser A; Vogelsang H; Reinisch W; Papay P
    Aliment Pharmacol Ther; 2016 Jul; 44(2):170-80. PubMed ID: 27226407
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Case of Crohn's Disease Initially Misdiagnosed as Intestinal Tuberculosis Due to Active Pulmonary Tuberculosis.
    Park S; Lee T; Lim W; Park S; Park H; Yun J; Kim D; Choi S; Oh H; Song C
    Korean J Gastroenterol; 2021 Jan; 77(1):30-34. PubMed ID: 33495429
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The safety and efficacy of adalimumab in patients with Crohn's disease: the experience of a single Canadian tertiary care centre.
    Teriaky A; Gregor J; Yan B; Ponich T; Chande N; Mosli M
    Scand J Gastroenterol; 2014 Mar; 49(3):280-6. PubMed ID: 24329040
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
    Bodini G; Giannini EG; Savarino V; Del Nero L; Pellegatta G; De Maria C; Baldissarro I; Savarino E
    Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy.
    Coburn LA; Wise PE; Schwartz DA
    Dig Dis Sci; 2006 Nov; 51(11):2045-7. PubMed ID: 17009112
    [No Abstract]   [Full Text] [Related]  

  • 47. [Level of adalimumab and its antibody titers define the effectiveness of the biological (anticytokine) therapy in Crohn's disease].
    Lazebnik LB; Sagynbaeva VÉ
    Eksp Klin Gastroenterol; 2013; (7):18-22. PubMed ID: 24772870
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn's disease patients on maintenance treatment with adalimumab.
    Ferreiro-Iglesias R; Barreiro-de Acosta M; Lorenzo-Gonzalez A; Dominguez-Muñoz JE
    Scand J Gastroenterol; 2016; 51(4):442-7. PubMed ID: 26595391
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Panaccione R; Schreiber S; Byczkowski D; Li J; Kent JD; Pollack PF
    Gastroenterology; 2007 Jan; 132(1):52-65. PubMed ID: 17241859
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan.
    Takeshima F; Yoshikawa D; Higashi S; Morisaki T; Oda H; Ikeda M; Machida H; Matsushima K; Minami H; Akazawa Y; Yamaguchi N; Ohnita K; Isomoto H; Ueno M; Nakao K
    BMC Gastroenterol; 2016 Jul; 16(1):82. PubMed ID: 27472988
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study.
    Papamichael K; Archavlis E; Lariou C; Mantzaris GJ
    J Crohns Colitis; 2012 Oct; 6(9):924-31. PubMed ID: 22424843
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Crohn's disease management after intestinal resection: a randomised trial.
    De Cruz P; Kamm MA; Hamilton AL; Ritchie KJ; Krejany EO; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Gibson PR; Sparrow M; Leong RW; Florin TH; Gearry RB; Radford-Smith G; Macrae FA; Debinski H; Selby W; Kronborg I; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Desmond PV
    Lancet; 2015 Apr; 385(9976):1406-17. PubMed ID: 25542620
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systematic Review and Meta-analysis: Adalimumab Monotherapy Versus Combination Therapy with Immunomodulators for Induction and Maintenance of Remission and Response in Patients with Crohn's Disease.
    Chalhoub JM; Rimmani HH; Gumaste VV; Sharara AI
    Inflamm Bowel Dis; 2017 Aug; 23(8):1316-1327. PubMed ID: 28719541
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomized controlled trials in maintenance of remission in Crohn's disease.
    D'Incà R; Caccaro R
    Rev Recent Clin Trials; 2012 Nov; 7(4):270-83. PubMed ID: 23092231
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
    Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
    Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adalimumab real-world dosage pattern and predictors of weekly dosing: patients with Crohn's disease in the United States.
    Loftus EV; Pan X; Zurawski P; Mulani P; Chao J
    J Crohns Colitis; 2011 Dec; 5(6):550-4. PubMed ID: 22115373
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
    Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
    Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The influence of infliximab and adalimumab on the expression of apoptosis-related proteins in lamina propria mononuclear cells and enterocytes in Crohn's disease - an immunohistochemical study.
    Eder P; Lykowska-Szuber L; Krela-Kazmierczak I; Stawczyk-Eder K; Zabel M; Linke K
    J Crohns Colitis; 2013 Oct; 7(9):706-16. PubMed ID: 23021876
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
    Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
    J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Term pregnancy in a patient with Crohn's disease under treatment with adalimumab].
    Sánchez Muñoz D; Hoyas Pablos E; Ramírez Martín Del Campo M; Núñez Hospital D; Guerrero Jiménez P
    Gastroenterol Hepatol; 2005; 28(7):435. PubMed ID: 16137481
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.